Jamie Denison-Pender

Jamie is the Founder and Corporate Development Officer. He has spent more than 20 years leading, growing and managing pharmaceutical-focused insight and advisory firms. In 2007, he became the managing director of a global competitive strategy firm and led the company’s transition from an industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient in 2010, led a management buyout in 2014 and the investment by Baird Capital in 2017 and Bridgepoint Development Capital (BDC) in 2021. During his tenure as Chief Executive Officer, Jamie drove more than 20 consecutive quarters of growth; the acquisition of Strategic North, a specialist provider of brand strategy and research support; and the expansion of Prescient’s suite of offerings to provide support to a range of pharma functions, including medical affairs, clinical development, early commercial, global marketing, competitive intelligence and market research. Jamie continues to sit on the Board of Directors and provides management with support and guidance.